← til store investorer
Gilead Sciences, Inc.
kapitalforvalter · portefølje $1.46 mia. · 5 positioner · rapport pr. 30.09.2026
Aktiepositioner rapport for 30.06.2026, indsendt 03.08.2026; ændring — mod 31.03.2026 · 6
| Selskab | Aktier | Værdi | % af porteføljen | Ændring i kvartalet |
|---|---|---|---|---|
| Arcus Biosciences Inc US:RCUS | 31 424 760 | $969 mio. | 58.76% | — |
| LAKEFRONT BIOTHERAPEUTICS NV US:LKFT | 16 707 477 | $500 mio. | 30.34% | — |
| Assembly Biosciences Inc US:ASMB | 4 977 089 | $137 mio. | 8.30% | +471 698 |
| Kyverna Therapeutics, Inc. US:KYTX | 4 126 119 | $36.8 mio. | 2.23% | — |
| Xilio Therapeutics Inc. CUSIP 98422T100 | 650 389 | $6.23 mio. | 0.38% | — |
| Arcellx Inc CUSIP 03940C100 | 0 (var 6 720 803) | — | — | solgt |
I virksomheder i vores database 4
| Selskab | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Arcus Biosciences Inc | 24.68% | 31 424 760 | 2026-06-30 |
| Assembly Biosciences Inc | 24.44% | 4 977 089 | 2026-06-30 |
| Xilio Development Inc | 9.88% | 650 389 | 2026-09-30 |
| Kyverna Therapeutics, Inc. | 6.67% | 4 126 119 | 2026-06-30 |
annonce
